cagrilintide and semaglutide 2.4 mg Coadministered in Adults with Overweight or Obesity Once-weekly cagrilintide for weight management

A very positive experience overall

While a study in chronic insomnia patients has reported that short-term DSIP administration is unlikely to be of major therapeutic benefit, a 16-month study in mice found that long-term DSIP administration increased maximum life span and decreased the rate of tumor growth [22, 23]

However, the evidence for PRP is somewhat stronger, and it has been used more extensively in clinical practice

On top of that, multiple doses can be administered if needed

Read the evidence A 2017 meta-analysis (N = 1,211) found that in patients with hyperuricaemia and CKD, urate-lowering treatment slowed renal function decline, limited proteinuria and reduced the relative risk of cardiovascular events or renal failure by over 50% 12 A 2020 meta-analysis (N = 6,458) found that urate-lowering treatment did not significantly reduce the risk of major adverse cardiovascular events, kidney failure or all-cause mortality